Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Business Segments — Stock-based compensation expense

Similar metrics at other companies

Hinge Health, Inc. logo
HNGEReportable Segment — Stock-based compensation expense
$11.69M+166,929%
Dolby Laboratories, Inc. logo
DLBReportable Segment — Stock-based compensation expense
$30.71M+0.1%
Twist Bioscience Corporation logo
TWSTReportable Segment — Stock-based compensation expense
$18.94M-6.8%
Archer Aviation logo
ACHRReportable Segment — Stock-based compensation expense
$70.4M+134%
Enphase Energy logo
ENPHReportable Segment — Stock-based compensation expense
$48.99M-11.9%
Trinet Group logo
TNETReportable Segment — Stock based compensation
$16M+23.1%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's business segments — stock-based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's business segments — stock-based compensation expense?
BioCryst Pharmaceuticals (BCRX) reported business segments — stock-based compensation expense of $16.03M in Q1 2026.
How has BioCryst Pharmaceuticals's business segments — stock-based compensation expense changed year-over-year?
BioCryst Pharmaceuticals's business segments — stock-based compensation expense decreased by 25.0% year-over-year, from $21.37M to $16.03M.
What does business segments — stock-based compensation expense mean?
Represents the non-cash expense recognized for equity-based awards granted to employees and executives within the segment. This metric is essential for understanding the total cost of human capital and the potential dilution impact on shareholders.